Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16202063 | 0.81 | PPARG (0.47) | LMNAPTBP1SMN1; SMN2PPARGPPARA | |
| SCHEMBL16202030 | 0.79 | RXRA (0.36) | LMNAPTBP1SMN1; SMN2PPARGPPARA | |
| SCHEMBL17217126 | 0.75 | RAB9A (0.39) | LMNAPTBP1SMN1; SMN2PPARGPPARA | |
| SCHEMBL15851072 | 0.75 | RAB9A (0.39) | LMNAPTBP1SMN1; SMN2PPARGPPARA | |
| SCHEMBL16202015 | 0.73 | SMN1; SMN2 (0.41) | LMNAPTBP1SMN1; SMN2PPARGPPARA | |
| SCHEMBL16202023 | 0.72 | GSK3B (0.32) | — | |
| SCHEMBL16202031 | 0.71 | — | — | |
| SCHEMBL16202066 | 0.71 | — | — | |
| SCHEMBL30445944 | 0.70 | NPC1 (0.47) | LMNAPTBP1SMN1; SMN2 | |
| SCHEMBL14100105 | 0.70 | NOS2 (0.42) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160249615-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | BASF SE (DE) | 2016-09-01 | — | — | US | disclosed |
| US-20160145219-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145202-A1 | Strobilurin Type Compounds for Combating Phytopathogenic Fungi | BASF SE (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160122327-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2016-05-05 | — | — | US | disclosed |
| US-9271501-B2 | Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors | BASF SE (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | BASF SE (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122327-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | SNX1, DPM1, SNU13 | LMNA 4479/4885PTBP1 2494/4885SMN1; SMN2 2653/4885 |
| US-20160145219-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | DPM1, CROCC, SNX1 | LMNA 4670/4885PTBP1 2745/4885SMN1; SMN2 3486/4885 |
| US-20160145202-A1 | Strobilurin Type Compounds for Combating Phytopathogenic Fungi | DPM1, CROCC, SNX1 | LMNA 4670/4885PTBP1 2745/4885SMN1; SMN2 3486/4885 |
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | SQOR, COX5B, UQCRB | LMNA 3613/4885PTBP1 2774/4885SMN1; SMN2 2724/4885 |
| US-20160249615-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | SQOR, COX5B, UQCRB | LMNA 3613/4885PTBP1 2774/4885SMN1; SMN2 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.